Cleave Therapeutics, Inc.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high-quality purified proteins and reagent solutions - notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents, and cell and gene therapy workflow solutions including T-Cell activation technologies. Bio-Techne’s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment.

Bio-Techne also develops and manufactures diagnostic products including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls, and other reagents for OEM and clinical customers. Bio-Techne’s genomic tools include advanced tissue-based in situ hybridization assays (ISH) for research and clinical use, sold under the ACD brand, as well as a portfolio of clinical molecular diagnostic oncology assays including the ExoDx®Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. These diagnostic and genomic products comprise Bio-Techne’s Diagnostics and Genomics Segment.

Bio-Techne products are integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $714 million in net sales in fiscal 2019 and has over 2,200 employees worldwide.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Our proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.

Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$6.5 billion molecular diagnostics market. Biocartis employs over 500 people and is headquartered in Mechelen, Belgium. Further information? Visit www.biocartis.com

Cellworks is a world leader in Precision Medicine. We help physicians and payers navigate to the most efficacious, cost-effective treatments for patients in a transparent and timely manner. Cellworks’ key therapeutic areas are Oncology, Immunology, Dermatology and Infectious Diseases. Cellworks’ unique bio-simulation platform is a unified representation of biological knowledge, curated from heterogeneous datasets, applied to finding cure. Since 2005, backed by Artiman Ventures and Sequoia Capital, Cellworks has the world’s strongest trans-disciplinary team of molecular biologists, cellular pathway modelers, and internet software technologists working towards a common goal – attacking serious diseases to improve the lives of patients.

Founded in 2002, CELPROGEN is a biotechnology company, with over 5000 products in the market, focused on developing stem cell research and therapeutics products for regenerative medicine in cardiology, oncology, diabetes & neurology. All of Celprogen’s biological products, including stem cells, cancer stem cells, iPC’s & media with specific ECM’s, are manufactured and produced in the United States of America.

CELPROGEN provides novel molecular diagnostics and therapeutic product development solutions for Biotechnology, Pharmaceutical, In-vitro diagnostics and academic partnership for drug discovery.

It has 3 divisions:

• Therapeutic Division: Focused on Drug Discovery efforts to develop Pharmaceutical agents and Drugs in the following categories: Cardiovascular, Diabetes, Neurological, Oncology,Renal and Metabolic disorders.
• Life Science Division: Provides research tools & solutions for assays, enzymes, antibodies, antigens, stem cells, Tissue culture expansion and differentiation media, primary and established cell cultures, tumor markers, cardiac markers, proteomic and genomic reagents and assay systems for life science academic and pharmaceutical communities.
• Device Division: Provides novel ELISA based assay, protein array, DNA array and cellular based assay systems that are cost effective for Research and In-vitro diagnostics Industries.

ProteoGenex is an established, innovative provider of biological specimens and clinical information of the highest quality standards.

We are a privately held US company founded in Los Angeles, CA in 2003. With headquarters in Culver City, CA, we also have a large, state-of-the-art research laboratory in Moscow, Russia.

The ProteoGenex team consists of 35 employees, including 30 Molecular Biologists, Cell Biologists, Biochemists, and Pathologists (15 PhDs, 5 MDs, 15 MSs).

Our biorepository offers an extensive inventory of biospecimens as well as an exclusive, custom-design human tissue-based research service, which is the company’s largest and fastest growing business segment.
Our unique and comprehensive biobank is composed of well-defined and categorized clinical samples, including frozen and FFPE tissues, blood, serum, plasma, bone marrow, tissue microarrays, etc. All ProteoGenex specimens are collected from a vast network of academic and professional clinical institutions under strict regulatory and ethical standards.

We have over 200,000 individual biomaterials covering disease targets in the fields of Oncology, Dermatology, Neurology, Immunology, Infectious Diseases, Autoimmune and Metabolic Disorders, and many more. Our products are derived from a variety of diseased human sources as well as from normal tissues. All specimens are supported by extensive pathology information and patient’s’ clinical history documentation.